Tilray Shares Preliminary Data From The Largest National Longitudinal Medical Cannabis Patient Study in Canada

Study finds significant reduction in opioid use and improvements in quality of life within first 6 months.

CANADA: Tilray Canada Ltd., a medical cannabis leader committed to advancing scientific knowledge of cannabinoids, shared preliminary data today from the Tilray Observational Patient Study (TOPS), a Tilray-sponsored survey of medical cannabis patients using Tilray products currently underway at 18 different medical clinics in five provinces in Canada. As Canada’s largest national medical cannabis longitudinal study, Read the full article…